Last reviewed · How we verify
Tadalafil and Sildenafil
At a glance
| Generic name | Tadalafil and Sildenafil |
|---|---|
| Also known as | Tadalafil/Cialis, Sildenafil/Viagra |
| Sponsor | Cedars-Sinai Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients (PHASE4)
- Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject (PHASE1)
- Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction (PHASE2)
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5
- A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants (PHASE1)
- Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (PHASE4)
- A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tadalafil and Sildenafil CI brief — competitive landscape report
- Tadalafil and Sildenafil updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI